argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
21 apr 2016 - 07:09
Statutaire naam
argenx SE
Titel
argenx and AbbVie to Collaborate on ARGX-115 Against Novel Immuno-Oncology
Bericht
--argenx Management to Discuss Collaboration on Conference Call Today at 6 pm CET / noon EDT--
BREDA, THE NETHERLANDS/GHENT, BELGIUM and NORTH CHICAGO, Ill., April 21, 2016 - AbbVie (NYSE: ABBV), a global biopharmaceutical company, and argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases will collaborate to develop and commercialize ARGX-115. ARGX-115 is argenx' preclinical-stage human antibody program targeting the novel immuno-oncology target GARP, a protein believed to contribute to immunosuppressive effects of T-cells.
Datum laatste update: 20 december 2025